REMED Co., Ltd.

REMED Co., Ltd.

KKRX:302550
2,590.00
KRW
-25.00
(-0.96%)
21.52EPS
43.63P/E
88.65BMarket Cap
Mar 23Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
310.03
341.16
715.12
555.13
660.35
697.49
605
833.74
791.69
878.62
Basic EPS, GAAP
1.8
-314.6
168.2
-61.2
24.6
130.6
26.02
234
17
66.59
Free Cash Flow per Basic Share
-34.88
-226.92
38.67
-209.2
-268.64
5.32
85.02
20.74
49.35
4.7
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
162.03
423.69
845.75
814.16
851.81
976.5
1,006.13
1,313.68
1,312.87
1,254.95
Tangible Book Value per Share
161.99
423.69
843.55
810.93
840.57
967.69
998.28
1,260.38
1,262.13
1,205.09
Basic Weighted Avg Shares
20
23
26
30
31
31
31
31
31
31
Sales/Revenue/Turnover
6,242
8,004
18,550
16,633
20,195
21,363
18,536
25,554
24,505
27,052
Operating Margin (%)
5.2
-10.45
23.11
10.12
5.56
7.78
-15.43
4.39
2.96
7.22
Depreciation Expense
234
245
387
395
561
756
955
1,278
1,417
1,432
Net Income, GAAP
36
-7,381
4,363
-1,834
752
4,000
797
7,172
526
2,050
Effective Tax Rate (%)
- -
- -
4.91
- -
14.81
13.35
67.41
8.26
- -
8.73
Profit Margin (%)
0.58
-92.21
23.52
-11.02
3.73
18.72
4.3
28.07
2.15
7.58
Working Capital
3,237
7,693
18,521
42,251
43,539
-1,212
5,191
19,615
18,308
15,217
LT Debt
3,538
6,618
5,858
15,688
16,367
2,869
2,329
5,363
2,767
2,706
Total Equity
4,185
10,945
24,624
24,787
26,098
30,002
30,794
40,270
39,464
37,173
Return on Invested Capital (%)
- -
- -
16.57
- -
2.15
3.04
-1.93
2.15
- -
4.04
Return on Capital (%)
- -
- -
18.3
- -
3.16
10.26
3.46
16.83
- -
7.21
Return on Common Equity (%)
- -
-97.56
24.53
-7.42
2.96
14.28
2.62
20.18
1.31
5.17

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,666
3,141
3,220
LT Borrowings
2,700
2,700
2,675
LT Finance Leases
67
54
31
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
31
Market Capitalization
93,690
90,181
88,655

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
27,783
28,843
26,582
Cash, Cash Equivalents & STI
13,029
12,384
10,548
Accounts Receivable, Net
6,410
8,260
7,753
Inventories
6,932
6,926
6,968
Total Current Liabilities
9,475
10,496
11,365
Payables & Accruals
- -
- -
- -
ST Debt
2,666
3,141
3,220
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
10.33%
-2%
Free Cash Flow
- -
298.75%
140.28%
Net Income, GAAP
- -
183.53%
-92.66%
Sales/Revenue/Turnover
- -
9.55%
-4.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,316
7,757
6,034
6,446
25,554
2025
6,443
5,554
5,812
6,695
24,505
2026
7,176
7,369
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3
35
119
82.93
234
2025
15
-5
14.36
-6.83
17
2026
36.22
23
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Geun-Yong Lee
Full Time Employees
114
Sector
Health technology
Industry
Medical specialties
Address
Cheongju-si South Korea
IPO Date
Aug 14, 2018
Website
remed.kr
Business
REMED Co., Ltd. is a South Korea-based medical device company that specializes in the research, development, manufacturing, and commercialization of non-invasive electromagnetic and acoustic stimulation systems for neurology, pain management, and medical aesthetics. Founded in 2003 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, the company operates across three primary business segments: Neuromodulation (Brain Stimulation), Neuromuscular Stimulation (Pain Management), and Medical Aesthetics. The company offers a comprehensive portfolio of medical and aesthetic equipment comprising: Transcranial Magnetic Stimulation (TMS) systems, including the ALTMS, BrainStim, and TAMAS series, which deliver non-invasive repetitive magnetic pulses to stimulate cortical neurons for the clinical treatment of major depressive disorder, stroke rehabilitation, Parkinson's disease, and psychiatric disorders; TMS navigation systems and localized coil apparatuses for precision brain mapping; Neuromuscular Stimulation (NMS) devices, including the Talent-A, Talent-Pro, Salus-Talent, Salus-Talent Pro, and Optimus-Pro systems, which utilize pulsed magnetic fields to stimulate deep motor nerves and muscles for chronic musculoskeletal pain relief and physical rehabilitation; Extracorporeal Shock Wave Therapy (ESWT) devices, encompassing radial and focused shockwave units for orthopedic therapy and soft tissue repair; and Aesthetic and Body Contouring systems, including the PERFECT, Tone-A, CoolFMS, and UI-Talent lines, designed for high-intensity electromagnetic muscle strengthening, body sculpting, and pelvic floor muscle stimulation for urinary incontinence treatment. In addition, REMED provides original equipment manufacturing (OEM) and original design manufacturing (ODM) solutions, supplying specialized electromagnetic power modules and therapeutic subsystems to multinational healthcare corporations. REMED distributes its products to hospitals, psychiatric facilities, rehabilitation clinics, orthopedic centers, dermatology practices, and aesthetic medical spas across domestic and international markets, including North America, Europe, Asia-Pacific, and Latin America, utilizing a global network of distributors alongside strategic partnerships with medical technology corporations such as Zimmer MedizinSysteme and Allergan Aesthetics. In recent operational and strategic developments, REMED has expanded its global commercial footprint by securing regulatory clearances, including European Medical Device Regulation (CE MDR) certifications and U.S. Food and Drug Administration (FDA) 510(k) clearances for its next-generation TMS and NMS systems; expanded OEM supply agreements for magnetic body contouring and pain therapy hardware; broadened clinical research and multi-center trials targeting expanded neurological indications such as dementia, sleep disorders, and pediatric developmental conditions; and introduced portable neuromodulation devices and AI-integrated navigation solutions to enhance therapeutic targeting and support decentralized care.